Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.52 |
| ▸ | CFD | P00746 | 1/20 | 0.51 |
| ▸ | F11 | P03951 | 1/20 | 0.51 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7166087 | 0.81 | CXCL8 (0.51) | ALOX5NR1H4ALDH1A1MAPT | |
| SCHEMBL8334964 | 0.80 | ALOX5 (0.70) | ALOX5MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL21711305 | 0.80 | NR1H4 (0.75) | NR1H4SUCNR1CFDF11TPSB2 | |
| SCHEMBL7875424 | 0.79 | ALOX5 (0.68) | ALOX5MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6864203 | 0.78 | ALOX5 (0.67) | ALOX5MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28328243 | 0.78 | MEN1 (0.70) | ALOX5MEN1KMT2AALDH1A1RORC | |
| SCHEMBL16396581 | 0.78 | NR1H4 (0.60) | NR1H4ALDH1A1SUCNR1CFDF11 | |
| SCHEMBL10904297 | 0.77 | ALOX5 (1.00) | ALOX5MEN1KMT2AMAPTRORC | |
| SCHEMBL5486512 | 0.76 | ALOX5 (0.64) | ALOX5MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7423527 | 0.74 | SLC16A3 (0.64) | NR1H4SUCNR1CFDF11TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | ALOX5 4159/4885MEN1 4428/4885KMT2A 2681/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | ALOX5 4159/4885MEN1 4428/4885KMT2A 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.